BCL2 and non-small cell lung carcinoma: For instance, Ko et al.’s research on 635 stage I non-small cell lung cancers (NSCLC) revealed a synergistic effect of cyclin A2 overexpression and negative Bcl-2 expression on worsening recurrence-free survival (RFS) [25].